

# 25

**amfAR**

The Foundation for AIDS Research  
Annual Report 2010

Making AIDS History

**amfAR**

25 <sup>yrs</sup>  
MAKING AIDS HISTORY

# Contents

<b>From the Chairman and the CEO</b>	03
<hr/>	
<b>amfAR in 2010: Selected Accomplishments</b>	04
<hr/>	
<b>Grants, Fellowships, and Awards</b>	06
Research Grants	
TREAT Asia Awards	
MSM Initiative Awards	
Public Policy Awards	
<hr/>	
<b>Message from the Treasurer and the Chair of the Finance and Budget Committee</b>	14
<hr/>	
<b>Financial Highlights</b>	15
<hr/>	
<b>Leadership and Advisory Committees</b>	18
Board of Trustees	
Scientific Advisory Committee	
Program Advisory Council	
Management Group	
<hr/>	

## From the Chairman and the CEO

As we commemorate amfAR's 25 years in the vanguard of the global response to HIV/AIDS, we find ourselves energized by a surge of momentum and vibrancy in the field of AIDS research. We sometimes struggle to explain the nature of this sea change that has made us more optimistic than ever before about our chances of finding a cure. Here's one way to think about it.

For many years, AIDS research focused almost exclusively on trying to define the enemy—mapping out the way in which HIV invaded the human body and set about destroying the immune system. It was a little like shining a flashlight in the dark. What you're able to see appears with great clarity. The trouble is, you're never really sure how vast the darkness is.

The research progress we've made in the last few years has effectively switched on the lights. Now, at last, we can see where we're going and chart a path forward. In fact, several potential pathways are now laid out before us. What was deemed naïve and unrealistic—even unmentionable—just a few years ago is now within the realm of possibility.

To capitalize on this momentum, in 2010 we launched a new research consortium for the express purpose of bringing teams of top scientists together to work collaboratively on the search for a cure. The greatest tribute we can pay to all who have dedicated their lives and their resources to our cause is to redouble our efforts to bring this epidemic to an end. With your continued partnership and generous support, we will do precisely that.



A handwritten signature in black ink, appearing to read "Kenneth Cole".

**Kenneth Cole**  
Chairman of the Board



A handwritten signature in black ink, appearing to read "Kevin Robert Frost".

**Kevin Robert Frost**  
Chief Executive Officer

**amfAR, The Foundation for AIDS Research,  
is dedicated to ending the global AIDS  
epidemic through innovative research.**

# amfAR in 2010: Selected Accomplishments



## Accelerating the Search for a Cure

Placing the search for a cure for HIV/AIDS firmly at the center of its research efforts, in May 2010 amfAR launched the Research Consortium for HIV Eradication (ARCHE), a bold new grant program supporting collaborative teams of biomedical researchers exploring the barriers to and potential for eradicating HIV infection. With first-round funding of more than \$1 million, ARCHE is supporting four groups of investigators who are exploring issues that are considered central to HIV eradication—work that is already starting to change the direction of AIDS research.



## Improving Treatment for Children

HIV-positive children consistently face greater disadvantages than adults when it comes to antiretroviral therapy. With the aim of improving access to higher quality pediatric HIV/AIDS care in Asia, amfAR's TREAT Asia program launched a two-year initiative to develop strategies to support lifelong care for HIV-positive children and generate clinical data that will inform pediatric treatment guidelines.

## Harnessing the Potential of Gene Therapy

amfAR announced its first ever awards for cutting-edge gene therapy research in February 2010, supporting a broad range of approaches to HIV prevention, treatment, and cure. These projects aim to subvert the process of HIV infection and eradicate the virus through strategies that thwart HIV directly or block its access to the cells it needs to replicate. Grantees are pursuing innovative approaches such as using a type of molecular scissors to lethally cut up the HIV genome; exploring a new and more efficient means of delivering gene therapy into a patient's body; and engineering and testing a variety of immune interventions that could be developed into a vaccine.

## Expanding the HIV Knowledge Base

During 2010, amfAR-funded investigators continued to advance and expand our understanding of HIV, publishing 35 peer-reviewed scientific papers in prestigious journals such as *Nature Medicine* and the *Journal of the American Medical Association*.

## Bringing a National AIDS Strategy to Life

When amfAR's public policy office opened in 1991, the Foundation identified the creation of a U.S. national HIV/AIDS strategy as a top goal. Finally, after two decades of unrelenting advocacy by amfAR and other AIDS organizations, President Obama unveiled the National HIV/AIDS Strategy in July 2010, setting specific goals for reducing HIV incidence, increasing access to care, and addressing health disparities.

## Toppling the Travel Ban

After years of persistent advocacy by amfAR and like-minded organizations, the U.S. government finally removed the ban on HIV-positive foreign visitors and immigrants on January 4, 2010. Three days later, the arrival of an HIV-positive man from Holland heralded a new era of unimpeded travel for people living with HIV and signaled the demise of a ban that was instituted in 1987.

## Tailoring Training

The expansion of HIV/AIDS treatment throughout Asia has brought hope to millions living with the virus, but it has also created a host of challenges for HIV clinicians and researchers as they try to stay abreast of the latest developments in this complex and rapidly changing field. To address the diversity of training needs across this vast region, TREAT Asia launched an innovative education program in 2010 that provides training in areas such as pediatrics research and lab capacity development tailored to the needs of specific settings.

## Meeting the HIV Needs of MSM

From South Africa to Ecuador and Ukraine to Vietnam, efforts to prevent and treat HIV/AIDS among men who have sex with men (MSM) in low- and middle-income countries received a substantial boost in 2010 from amfAR's MSM Initiative. Through the Initiative—which concentrates its efforts in countries where HIV among MSM is severely neglected—amfAR made 41 community awards to grassroots groups in 35 countries, bringing the number of awards since the program's inception in 2007 to 101. Many of the 2010 projects built on work funded by previous awards, a testament to the growing effectiveness of MSM Initiative grantees.

## Standing Up for Human Rights

MSM in many parts of the world face increasing levels of homophobic and transphobic rhetoric and violence, which impede access to vital HIV prevention, treatment, and care services for marginalized populations that are often at high risk of infection. During 2010, amfAR spoke out frequently, publicly, and emphatically in support of the human rights that are inextricably linked with public health and the fight against HIV/AIDS.



## 2010 Research Fellowships, Grants, And Awards

All projects listed below were supported by amfAR during the period October 1, 2009, to September 30, 2010. Grants funded during fiscal year 2010 but awarded in previous years are shown with the year of the award in parenthesis.

### amfAR RESEARCH CONSORTIUM ON HIV ERADICATION (ARCHE)

#### Inflammation and HIV persistence

Principal Investigator: Joseph McCune, M.D., Ph.D.  
University of California, San Francisco  
San Francisco, CA  
\$360,000

Collaborating Investigator: Steven Deeks, M.D.  
University of California, San Francisco  
San Francisco, CA

#### Characterizing and targeting persistent

##### HIV viremia

Principal Investigator: Sarah Palmer, Ph.D.  
Swedish Institute for Infectious Disease Control,  
Karolinska Institute  
Solna, Sweden  
\$360,000

Collaborating Investigator: Frederick Hecht, M.D.  
University of California, San Francisco  
San Francisco, CA

#### Using approved drugs to target latent HIV

Principal Investigator: Robert F. Siliciano, M.D., Ph.D.  
Johns Hopkins University  
Baltimore, MD  
\$360,000

Collaborating Investigator: Janice E. Clements,  
Ph.D.  
Johns Hopkins University  
Baltimore, MD

#### Quantitating virus in patients receiving either non-ablative or total ablative treatment

Principal Investigator: John Zaia, M.D.  
Beckman Research Institute of City of Hope  
Duarte, CA  
\$120,000

### MATHILDE KRIM FELLOWS IN BASIC BIOMEDICAL RESEARCH

#### Pursuing HIV Eradication

##### Studies of HIV-1 latency and reactivation using a novel ex-vivo model

Alberto Bosque, Ph.D.  
University of Utah  
Salt Lake City, UT  
\$125,000 (2009)

##### Macrophage-T cell interactions in formation of the HIV-1 reservoir

Fedde Groot, Ph.D.  
University of Oxford  
Oxford, United Kingdom  
\$124,782 (2009)

##### Novel post-transcriptional mechanisms of HIV-1 latency and reactivation

Kara Lassen, Ph.D.  
The J. David Gladstone Institutes  
San Francisco, CA  
\$102,340 (2008)

#### Optimizing Treatment

##### CCR5 heterogeneity and mechanism of viral resistance to CCR5 inhibitors

Reem Berro, Ph.D.  
Weill Medical College of Cornell University  
New York, NY  
\$125,000

##### Mechanisms of Vpx and Vpr targeted restriction factors

Thomas Gramberg, Ph.D.  
New York University School of Medicine  
New York, NY  
\$125,000

##### Morphogenesis and storage of HIV-1 particles

Nolwenn Jouvenet, Ph.D.  
Aaron Diamond AIDS Research Center  
New York, NY  
\$125,000 (2008)

##### Contribution of E3 ubiquitin ligase activity to HIV-1 restriction by TRIM5

Felipe Diaz-Griffero, Ph.D.  
Albert Einstein College of Medicine of Yeshiva University  
Bronx, NY  
\$80,000 (Phase II Funding)

##### Characterization of transportin-SR2 mediated nuclear import of HIV

Jan De Rijck, Ph.D.  
Katholieke Universiteit Leuven  
Leuven, Belgium  
\$125,000 (2009)

##### Ultrapotent inhibitors of wild-type and multi-drug resistant HIV

Bruno Marchand, Ph.D.  
University of Missouri-Columbia  
Columbia, MO  
\$125,000 (2008)

##### Structural mechanisms for nuclear export of HIV-1 REV by CRM1

Xiuhua Dong, M.D., Ph.D.  
University of Texas Southwestern Medical Center at Dallas  
Dallas, TX  
\$125,000

##### Biophysical and structural studies of the HIV integrase DNA complex

Kushol Gupta, Ph.D.  
University of Pennsylvania School of Medicine  
Philadelphia, PA  
\$125,000 (2008)

##### Maintenance of drug resistance mutations and HIV-1 evolutionary adaptation

Morgane Rolland, Ph.D.  
University of Washington  
Seattle, WA  
\$125,000 (2008)

#### Preventing HIV Transmission

##### Evaluation of the immunogenicity of "evolved" stable HIV-1 Env trimers

Rogier Sanders, Ph.D.  
Academic Medical Center of the University of Amsterdam  
Amsterdam, Netherlands  
\$62,675 (Phase II)

##### Generation of stable HIV-1 Env trimers through virus evolution

Rogier Sanders, Ph.D.  
Academic Medical Center, University of Amsterdam  
Amsterdam, Netherlands  
\$125,000 (2008) (Phase I)

##### A chemical campaign to identify HIV-1 entry inhibitors

Navid Madani, Ph.D.  
Dana-Farber Cancer Institute, Harvard Medical School  
Boston, MA  
\$125,000 (2009)

## RESEARCH FELLOWSHIPS

### Pursuing Eradication

#### Direct injectable cell targeting vectors for improved HIV gene therapy

Joseph Anderson, Ph.D.  
University of California, Davis  
Davis, CA  
\$125,000

#### Creation of a synergistic immune response to HIV by gene therapy

Alejandro Balazs, Ph.D.  
California Institute of Technology  
Pasadena, CA  
\$125,000

### Optimizing Treatment

#### Identifying cellular cofactors of rhesus monkey TRIM5-alpha

Devin Christensen, Ph.D.  
University of Utah  
Salt Lake City, UT  
\$125,000 (2009)

### Preventing HIV Transmission

#### Cell phone use among MSM in stigmatized settings: Implications for HIV

Joyce Nyoni, Ph.D.  
University of Dar es Salaam  
Dar es Salaam, Tanzania  
\$114,110 (2009)

## RESEARCH GRANTS

### Pursuing HIV Eradication

#### Combination of CCR5Δ32 and siRNAs targeting HIV

Lung-Ji Chang, Ph.D.  
University of Florida  
Gainesville, FL  
\$120,000

#### Engineering and characterization of HIV-specific homing endonucleases

Keith Jerome, M.D., Ph.D.  
University of Washington  
Seattle, WA  
\$120,000

#### Using homologous recombination to stack genetic resistance to HIV infection

Matthew Porteus, M.D., Ph.D.  
University of Texas Southwestern Medical Center  
Dallas, TX  
\$120,000

#### Engineer pluripotent stem cell derived NK cells to kill HIV infection

Zhenya Ni, Ph.D.  
University of Minnesota  
Minneapolis, MN  
\$125,000

#### In vivo modeling of HIV persistence and its eradication

Paul Denton, Ph.D.  
University of Texas Southwestern Medical Center at Dallas  
Dallas, TX  
\$125,000 (2008)

#### Cellular factors required for HIV cell-to-cell transmission

Jing Jin, Ph.D.  
Yale University School of Medicine  
New Haven, CT  
\$125,000 (2009)

#### The role of mental health issues in HIV acquisition among female drug users

Gail Gilchrist, Ph.D.  
L'Institut Municipal d'Investigacio Medica  
Barcelona, Spain  
\$124,915 (2008)

#### In vivo virus persistence during suppressive therapy in the RT-SHIV model

Zandrea Ambrose, Ph.D.  
University of Pittsburgh  
Pittsburgh, PA  
\$120,000 (2008)

#### Animal model for controlled SIV infection

Cristian Apetrei, M.D., Ph.D.  
Tulane University  
New Orleans, LA  
\$119,687 (2008)

#### Autophagy and intracellular HIV in macrophages

Vojo Deretic, Ph.D.  
University of New Mexico Health Sciences Center  
Albuquerque, NM  
\$120,000 (2008)

#### HDAC inhibition and chromatin remodeling to disrupt proviral latency

David Margolis, M.D.  
University of North Carolina at Chapel Hill  
Chapel Hill, NC  
\$120,000 (2008)

#### In vivo modeling of HIV persistence and its eradication

Paul Denton, Ph.D.  
University of North Carolina at Chapel Hill  
Chapel Hill, NC  
\$63,483 (transfer) (2008)

#### Viral persistence in the MGT of RT-SHIV infected macaques on HAART

Miranda Xhilaga, Ph.D.  
Monash University  
Melbourne, Australia  
\$125,000 (2007)

#### What they're not telling me: Veterans, trust, and HIV management

Kristin Mattocks, Ph.D.  
Yale University  
New Haven, CT  
\$108,480 (2008)

#### Impulsivity, drug abuse, and HIV medication adherence: An fMRI study

Christina Meade, Ph.D.  
Duke University  
Durham, NC  
\$49,533 (2007)

#### Anal intercourse, STIs, and HIV among STD clinic clients

Marjan Javanbakht, Ph.D.  
University of California, Los Angeles  
Los Angeles, CA  
\$112,193 (2007)

#### Treatment intensification: Effects on persistent viremia

Sarah Palmer, Ph.D.  
Swedish Institute for Infectious Disease Control, Karolinska Institute  
Solna, Sweden  
\$120,000 (2008)

#### IL-7 and antigen driven proliferation generate distinct HIV reservoirs

Rafick-Pierre Sékaly, Ph.D.  
Université de Montréal, Centre de Recherche du CHUM  
Montréal, Canada  
\$106,164 (2008)

#### Quantification of HIV provirus: Integration and replication competence

Celsa Spina, Ph.D.  
Veterans Medical Research Foundation  
San Diego, CA  
\$117,600 (2008)

## Optimizing Treatment

Evaluating healthy living curriculum for HIV-infected youth

*A New York State HIV Research Centers Consortium Grant*

Susan Abramowitz, Ph.D.  
New York University School of Medicine  
New York, NY  
\$32,999

Effectiveness of a collaborative model of HIV primary care in the Bronx

*A New York State HIV Research Centers Consortium Grant*

Carolyn Chu, M.D.  
Montefiore Medical Center  
Bronx, NY  
\$33,000

High-throughput screens for inhibitors of Vif-APOBEC3G interaction

Dana Gabuzda, M.D.  
Dana-Farber Cancer Institute, Inc.  
Boston, MA  
\$120,000 (2009)

## Preventing HIV Transmission

A pilot study of a text messaging-enhanced POL HIV intervention program

Hongjie Liu, Ph.D.  
Virginia Commonwealth University  
Richmond, VA  
\$119,894 (2009)

Assessing internet users' preferences for structural and network interventions

Willi McFarland, M.D.  
San Francisco Department of Health  
San Francisco, CA  
\$102,421 (2009)

## RESEARCH AWARDS

### Optimizing Treatment

HIV/AIDS and aging: Emerging issues in research, care, treatment and prevention

Judith Auerbach, Ph.D.  
San Francisco AIDS Foundation  
San Francisco, CA  
\$5,500

The role of PIP2 as a cofactor for HIV-1 assembly at the plasma membrane

Akira Ono, Ph.D.  
University of Michigan  
Ann Arbor, MI  
\$120,000 (2009)

Target of Vpr/Vpx Restriction

Lee Ratner, M.D., Ph.D.  
Washington University School of Medicine  
St. Louis, MO  
\$120,000 (2009)

An evolutionary approach to identifying robust antiretroviral drug targets

Sara Sawyer, Ph.D.  
University of Texas at Austin  
Austin, TX  
\$120,000 (2009)

Mistrust of evidence-based medicine affects health outcomes of Latinos

Scott Rhodes, Ph.D.  
Wake Forest University Health Sciences  
Winston-Salem, NC  
\$120,000 (2008)

Neurocognitive factors in the relationship between drug use and risky sex

Sarit Golub, Ph.D.  
Research Foundation of the City of New York  
Flushing, NY  
\$120,000 (2008)

HIV prevention efficacy beliefs about male circumcision in South Africa

Joanne Mantell, Ph.D.  
HIV Center for Clinical and Behavioral Studies at the New York State Psychiatric Institute and Columbia University  
New York, NY  
\$119,906 (2008)

International consensus meeting on AIDS-related CMV retinitis

Gary N. Holland, M.D.  
University of California, Los Angeles  
Los Angeles, CA  
\$25,000

HIV conspiracy beliefs among MSM in inner-city slum area of Johannesburg

Waimar Tun, Ph.D.  
Population Council  
New York, NY  
\$119,977 (2008)

CDC HIV testing guidelines: Unresolved ethical concerns

Roland Merchant, M.D., Sc.D.  
Rhode Island Hospital  
Providence, RI  
\$120,000 (2007)

The impact of stigma on access to HIV treatment and care

Jennifer Sayles, M.D.  
University of California, Los Angeles, David Geffen School of Medicine  
Los Angeles, CA  
\$120,000 (2007)

Immunologic benefits of CCR5 inhibitor intensification

Robert Shafer, M.D.  
Palo Alto Veterans Administration Medical Center and Stanford University  
Palo Alto, CA  
\$107,644 (2007)

Minority stress, social support, and sexual risk in South African MSM

Theodorus Sandfort, Ph.D.  
Research Foundation for Mental Hygiene, Inc.  
New York, NY  
\$119,836 (2008)

Epithelial injury and HIV penetration after simulated ejaculation

Craig Hendrix, M.D.  
Johns Hopkins University School of Medicine  
Baltimore, MD  
\$120,000 (2007)



## TREAT Asia Grants and Awards

All projects listed below were supported by amfAR during the period October 1, 2009, to September 30, 2010. Grants funded during fiscal year 2010 but awarded in previous years are shown with the year of the award in parentheses.

### ASIA PACIFIC HIV OBSERVATIONAL DATABASE (APHOD)

Matthew G. Law, Ph.D.  
University of New South Wales  
Coogee, Australia  
\$332,278 (Year 5)  
\$279,293 (2009–Year 4)

### TREAT ASIA HIV OBSERVATIONAL DATABASE (TAHOD)

Huy Bui, Ph.D., M.D.  
National Hospital of Tropical Diseases  
Hanoi, Vietnam  
\$15,000 (Year 5)

Yi-Ming Chen, M.D., Sc.D.  
National Yang-Ming University  
Taipei, China  
\$15,000 (Year 5)  
\$15,000 (2009–Year 4)  
\$1,920 (2009–Tuberculosis Expansion of Work–Year 4)

Jun Yong Choi, M.D., Ph.D.  
Yonsei University College of Medicine  
Seoul, South Korea  
\$15,000 (Year 5)  
\$15,000 (2009–Year 4)  
\$1,280 (2009–Tuberculosis Expansion of Work–Year 4)

Rossana Ditungco, M.D.  
Asian Foundation for Tropical Medicine, Inc.  
Muntinlupa City, Philippines  
\$15,000 (Year 5)  
\$15,000 (2009–Year 4)  
\$6,720 (2009–Tuberculosis Expansion of Work–Year 4)

Adeeba Kamarulzaman, F.R.A.C.P.  
University of Malaya  
Kuala Lumpur, Malaysia  
\$15,000 (Year 5)  
\$15,000 (2009–Year 4)  
\$960 (2009–Tuberculosis Expansion of Work–Year 4)

Nagalingeswaran Kumarasamy, M.D., M.B.B.S., Ph.D.  
YRG Centre for AIDS Research and Education, VHS  
Chennai, India  
\$15,000 (Year 5)  
\$15,000 (2009–Year 4)  
\$12,720 (2009–Tuberculosis Expansion of Work–Year 4)

Christopher Lee, M.B.B.S., M.R.C.P.  
Sungai Buloh Hospital  
Sungai Buloh, Malaysia  
\$15,000 (Year 5)  
\$15,000 (2009–Year 4)  
\$1,920 (2009–Tuberculosis Expansion of Work–Year 4)

Patrick Li, M.B.B.S.  
Queen Elizabeth Hospital  
Hong Kong SAR, China  
\$15,000 (Year 5)  
\$15,000 (2009–Year 4)  
\$800 (2009–Tuberculosis Expansion of Work–Year 4)

Poh Lian Lim, M.D., M.P.H.  
Tan Tock Seng Hospital  
Singapore  
\$15,000 (Year 5)  
\$15,000 (2009–Year 4)  
\$640 (2009–Tuberculosis Expansion of Work–Year 4)

Tuti Parwati Merati, M.D.  
Udayana University School of Medicine  
Denpasar, Indonesia  
\$15,000 (Year 5)  
\$15,000 (2009–Year 4)  
\$5,600 (2009–Tuberculosis Expansion of Work–Year 4)

Shinichi Oka, M.D.  
National Center for Global Health and Medicine  
Shinjuku, Japan  
\$15,000 (Year 5)  
\$15,000 (2009–Year 4)  
\$880 (2009–Tuberculosis Expansion of Work–Year 4)

Praphan Phanuphak, M.D., Ph.D.  
HIV-NAT/Thai Red Cross AIDS Research Center  
Bangkok, Thailand  
\$15,000 (Year 5)  
\$15,000 (2009–Year 4)  
\$2,880 (2009–Tuberculosis Expansion of Work–Year 4)

Sanjay Pujari, M.D.  
Institute of Infectious Diseases  
Pune, India  
\$15,000 (Year 5)  
\$15,000 (2009–Year 4)  
\$3,280 (2009–Tuberculosis Expansion of Work–Year 4)

Thira Sirisanthana, M.D.  
Chiang Mai University  
Chiang Mai, Thailand  
\$15,000 (Year 5)  
\$15,000 (2009–Year 4)  
\$4,880 (2009–Tuberculosis Expansion of Work–Year 4)

Somnuek Sungkanuparph, M.D.  
Sasisopin Kiertiburanakul, M.D. (Year 5)  
Ramathibodi Hospital, Mahidol University  
Bangkok, Thailand  
\$15,000 (Year 5)  
\$15,000 (2009–Year 4)  
\$3,200 (2009–Tuberculosis Expansion of Work–Year 4)

Pham Thuy, M.D.  
Bach Mai Hospital  
Hanoi, Vietnam  
\$15,000 (Year 5)

Saphonn Vonthanak, M.D., Ph.D.  
National Center for HIV/AIDS, Dermatology and STDs  
Phnom Penh, Cambodia  
\$15,000 (Year 5)  
\$15,000 (2009–Year 4)  
\$7,600 (2009–Tuberculosis Expansion of Work–Year 4)

Evy Yuniastuti, M.D.  
Cipto Mangunkusumo General Hospital  
Jakarta Pusat, Indonesia  
\$15,000 (Year 5)  
\$15,000 (2009–Year 4)  
\$12,800 (2009–Tuberculosis Expansion of Work–Year 4)

Fujie Zhang, M.D.  
Beijing Ditan Hospital  
Beijing, China  
\$15,000 (Year 5)  
\$15,000 (2009–Year 4)  
\$1,200 (2009–Tuberculosis Expansion of Work–Year 4)

#### [Identifying biomarkers of anal intraepithelial neoplasia in Thai MSM](#)

Jintanat Ananworanich, M.D., and Nittaya Phanuphak, M.D.  
HIV-NAT/Thai Red Cross AIDS Research Center  
Bangkok, Thailand  
\$92,000 (Year 2)  
\$52,000 (Supplemental Funding to Year 1)  
\$60,000 (2009 Year 1)

#### [International collaboration for testing discordant subtypes](#)

Yi-Ming Chen, M.D., Sc.D.  
National Yang-Ming University  
Taipei, China  
\$20,000

#### [Clinical epidemiology of cancer among PLHA in Taiwan](#)

Yi-Ming Chen, M.D., Sc.D.  
National Yang-Ming University  
Taipei, China  
\$50,000 (Year 3)  
\$70,000 (2009–Year 2)

#### [Multidisciplinary services to enhance HIV testing and linkage to care among MSM](#)

Praphan Phanuphak, M.D., Ph.D.  
HIV-NAT/Thai Red Cross AIDS Research Center  
Bangkok, Thailand  
\$235,040

#### [Glomerular filtration rate estimation in HIV-infected Thai patients](#)

Praphan Phanuphak, M.D., Ph.D.  
HIV-NAT/Thai Red Cross AIDS Research Center  
Bangkok, Thailand  
\$20,000

#### [Determinants of HIV disease progression and treatment outcomes among MSM in the Philippines](#)

Rossana Ditungco, M.D.  
Asian Foundation for Tropical Medicine, Inc.  
Muntinlupa City, Philippines  
\$20,000

## AUSTRALIAN HIV OBSERVATIONAL DATABASE (AHOD)

Debra Allen, M.B.Ch.B., Dip Med. Northern Sydney Central Coast Area Health Services Holden Street Clinic Gosford, Australia \$1,275 (Year 5) \$1,200 (2009–Year 4)	Eva Jackson, M.D. Blue Mountains Sexual Health and HIV Clinic Katoomba, Australia \$1,575 (Year 5) \$1,725 (2009–Year 4)	Darren Russell, M.D. Cairns Sexual Health Service Cairns, Australia \$6,000 (Year 5) \$7,500 (2009–Year 4)
Katherine Brown, M.D. South East Sydney Illawarra Area Health Service Warrawong, Australia \$1,500 (Year 5) \$1,725 (2009–Year 4)	Eva Jackson, M.D. Nepean Hospital Sydney, Australia \$1,350 (Year 5) \$1,350 (2009–Year 4)	David Smith Sexual Health and AIDS Services Lismore, Australia \$6,375 (Year 5) \$6,000 (2009–Year 4)
Andrew Carr, M.D. St. Vincent's Hospital Sydney Darlinghurst, Australia \$7,200 (Year 5) \$7,500 (2009–Year 4)	Mark Kelly, M.B.B.S. Prince Charles Hospital, AIDS Medical Unit Brisbane, Australia \$6,300 (Year 5) \$7,350 (2009–Year 4)	David Sowden, M.B.B.S. Nambour General Hospital Nambour, Australia \$7,500 (Year 5) \$7,500 (2009–Year 4)
John Chuah, M.B.B.S., B.S.M.D. Gold Coast Health Service District Miami, Australia \$7,500 (Year 5) \$7,500 (2009–Year 4)	Anuja Kulatunga Northern Territory Department of Health Casuarina, Australia \$1,425 (Year 5) \$1,200 (2009–Year 4)	Sharon Taylor, C.N.C. Tamworth Sexual Health Service Tamworth, Australia \$825 (Year 5) \$600 (2009–Year 4)
William Donohue, M.B.B.S. University of Adelaide, Care and Prevention Program Adelaide, Australia \$2,100 (Year 5) \$2,100 (2009–Year 4)	David Nolan Royal Perth Hospital Perth, Australia \$7,500 (Year 5) \$7,500 (2009–Year 4)	David Templeton, Ph.D. RPA Sexual Health Clinic Camperdown, Australia \$675 (Year 5) \$600 (2009–Year 4)
Jennifer Hoy, M.B.B.S. Victorian HIV Service, Alfred Hospital Melbourne, Australia \$6,525 (Year 5) \$6,975 (2009–Year 4)	Tim Read Melbourne Sexual Health Centre Carlton, Australia \$5,550 (Year 5) \$6,075 (2009–Year 4)	Ian Woolley, M.B.B.S., F.R.A.C.P. Monash Medical Centre–Clayton Melbourne, Australia \$4,425 (Year 5) \$4,825 (2009–Year 4)
	Norman Roth, M.B.B.S., FA.Ch.S.H.M. Prahlan Market Clinic Pty, Ltd. South Yarra, Australia \$7,125 (Year 5) \$7,500 (2009–Year 4)	Lynne Wray, M.B.B.S. Sydney Sexual Health Centre, Sydney Hospital Sydney, Australia \$3,675 (Year 5) \$3,675 (2009–Year 4)

## TREAT ASIA PEDIATRIC HIV OBSERVATIONAL DATABASE (TApHOD)

Jintanat Ananworanich, M.D., Ph.D. HIV-NAT/Thai Red Cross AIDS Research Center Bangkok, Thailand \$10,000 (Year 4) \$800 (Tuberculosis Expansion of Work–Year 4) \$15,000 (2009–Year 3)	Nia Kurniati, M.D. Cipto Mangunkusumo General Hospital Jakarta, Indonesia \$7,500 (Year 4) \$3,350 (Tuberculosis Expansion of Work–Year 4) \$7,500 (2009–Year 3)	Nik Khairulddin Nik Yusoff, M.D. Hospital Raja Perempuan Zainab II Kota Bharu, Malaysia \$7,500 (Year 4) \$800 (Tuberculosis Expansion of Work–Year 4) \$7,500 (2009–Year 3)
Kulkanya Chokeyphaibulkit, M.D. Siriraj Hospital Mahidol University Bangkok, Thailand \$10,000 (Year 4) \$5,750 (Tuberculosis Expansion of Work–Year 4) \$20,000 (2009–Year 3)	Matthew G. Law, Ph.D. University of New South Wales Coogee, Australia \$161,157 (Year 4) \$119,665 (2009–Year 3) \$19,000 (2009–Supplemental Funding–Year 3)	Kamarul Razali, M.D. Pediatric Institute, Hospital Kuala Lumpur Kuala Lumpur, Malaysia \$7,500 (Year 4) \$7,500 (2009–Year 3)
Khu Thi Khanh Dung, Ph.D., M.D. National Hospital of Pediatrics Hanoi, Vietnam \$50,000 (Year 4)	Pagakrong Lumbiganon, M.D. Khon Kaen University Khon Kaen, Thailand \$15,000 (Year 4) \$8,000 (Tuberculosis Expansion of Work–Year 4) \$15,000 (2009–Year 3)	Virat Sirisanthana, M.D. Chiang Mai University—Research Institute for Health Sciences Chiang Mai, Thailand \$15,000 (Year 4) \$1,000 (Tuberculosis Expansion of Work–Year 4) \$15,000 (2009–Year 3)
Rawiwan Hansudewechakul, M.D. Chiang Rai Prachanukroh Hospital Muang, Thailand \$20,000 (Year 4) \$2,650 (Tuberculosis Expansion of Work–Year 4) \$20,000 (2009–Year 3)	Fong Siew Moy, M.D. Hospital Likas Kota Kinabalu, Malaysia \$7,500 (Year 4) \$7,500 (2009–Year 3)	Saphonn Vonthanak, M.D. National Center for HIV/AIDS, Dermatology and STDs Phnom Penh, Cambodia \$20,000 (Year 4) \$4,400 (Tuberculosis Expansion of Work–Year 4) \$20,000 (2009–Year 3 Funding)
Nagalingeswaran Kumarasamy, M.D., M.B.B.S., Ph.D. YRG Centre for AIDS Research and Education, VHS Chennai, India \$7,500 (Year 4) \$9,450 (Tuberculosis Expansion of Work–Year 4) \$2,250 (Supplemental Funding–Year 4) \$20,000 (2009–Year 3)	Revathy Nallusamy, M.B.B.S. Penang Hospital Georgetown, Malaysia \$2,500 (Year 4) \$2,500 (2009–Year 3)	<a href="#">Prevalence of HPV and intraepithelial neoplasia biomarkers in adolescents</a> Jintanat Ananworanich, M.D., Ph.D. HIV-NAT/Thai Red Cross AIDS Research Center Bangkok, Thailand \$15,000

## TREAT ASIA PEDIATRIC HIV OBSERVATIONAL DATABASE (TApHOD) (Continued)

### [HIV and HBV co-infection among prenatally HIV-infected adolescents in Asia](#)

Linda Aurrpibul, M.D.  
Chiang Mai University  
Chiang Mai, Thailand  
\$10,000

### [Bone mineral density among HIV-infected adolescents](#)

Kulkanya Chokeyhaibulkit, M.D.  
Siriraj Hospital  
Mahidol University  
Bangkok, Thailand  
\$15,000

### [Optimizing HIV treatment for children in Asia: Developing strategies for lifelong Care](#)

Praphan Phanuphak, M.D., Ph.D.  
HIV-NAT/Thai Red Cross AIDS Research Center  
Bangkok, Thailand  
\$215,380

### [Our Village](#)

John Tucker  
New Hope for Cambodian Children  
Killeen, Texas  
\$37,320

## TREAT ASIA QUALITY ASSURANCE SCHEME (TAQAS)

Matthew G. Law, Ph.D.  
University of New South Wales  
Coogee, Australia  
\$85,470 (Year 5)  
\$209,787 (2009–Year 4)

## TREAT ASIA STUDIES TO EVALUATE RESISTANCE (TASER)

Rossana Ditangco, M.D.  
Asian Foundation for Tropical Medicine, Inc.  
Muntinlupa City, Philippines  
\$82,200 (Year 4)  
\$66,000 (2009–Year 3)

Matthew G. Law, Ph.D.  
University of New South Wales  
Coogee, Australia  
\$191,236 (Year 4)  
\$249,713 (2009–Year 3)

Praphan Phanuphak, M.D., Ph.D.  
HIV-NAT/Thai Red Cross AIDS Research Center  
Bangkok, Thailand  
\$87,200 (Year 4)  
\$66,000 (2009–Year 3)

Adeeba Kamarulzaman, F.R.A.C.P.  
University of Malaya  
Kuala Lumpur, Malaysia  
\$62,900 (Year 4)  
\$66,000 (2009–Year 3)

Christopher Lee, M.B.B.S., M.R.C.P.  
Sungai Buloh Hospital  
Sungai Buloh, Malaysia  
\$65,400 (Year 4)  
\$66,000 (2009–Year 3)

Winai Ratanasuwan, M.D.  
Siriraj Hospital, Mahidol University  
Bangkok, Thailand  
\$60,400 (Year 4)

Pacharee Kantipong, M.D.  
Chiang Rai Regional Hospital  
Chiang Rai, Thailand  
\$65,400 (Year 4)  
\$68,500 (2009–Year 3)

Tuti Parwati Merati, M.D.  
Udayana University School of Medicine  
Denpasar, Indonesia  
\$62,900 (Year 4)  
\$66,000 (2009–Year 3)

Thira Sirisanthana, M.D.  
Chiang Mai University  
Chiang Mai, Thailand  
\$65,400 (Year 4)  
\$66,000 (2009–Year 3)

Mahiran Mustafa, M.D.  
Hospital Raja Perempuan Zainab II  
Kota Bharu, Malaysia  
\$60,400 (Year 4)

Somnuek Sungkanuparph, M.D.  
Ramathibodi Hospital, Mahidol University  
Bangkok, Thailand  
\$105,720 (Year 4)  
\$82,000 (2009–Year 3)

## OTHER RESEARCH FUNDING

### [Randomized open-label study of second-line combination ART](#)

David Cooper, M.D.  
University of New South Wales  
Darlinghurst, Australia  
\$125,000

## PURPLE SKY NETWORK / MSM ADVOCACY PROJECTS

### [Building environment for MSM/TG in Cambodia to access friendly health services](#)

Men's Health Social Services  
Phnom Penh, Cambodia  
\$10,000

### [Advocacy skills and HIV treatment access for MSM and transgender persons](#)

Lao Youth Action Programme under the Lao Buddhist Fellowship Programme  
Vientiane, Lao PDR  
\$10,000

### [Advocacy to increase resources and mobilize the participation of the MSM community in the HIV response in Vietnam](#)

Institute for Social Development  
Hanoi, Vietnam  
\$9,900

## TREAT ASIA COMMUNITY PROGRAM AWARDS

Tao Cai  
AIDS Care China  
Kunming, China  
\$3,000 (Positive Commitment Award Event Support)  
\$10,584 (Bridge Funding)  
\$70,500 (2009–HIV/AIDS Treatment Literacy Training)

## 2010 MSM Initiative Awards and Community Awards

All projects listed below received awards from amfAR during the period October 1, 2009, to September 30, 2010. Some organizations have requested anonymity to protect the safety of their staff and clients.

### MSM INITIATIVE COMMUNITY AWARDS

#### Africa

##### The Access Project Extended

Alternatives-Cameroun  
Douala, Cameroon  
\$15,000

##### Project for STI/HIV Prevention and Care for Highly Vulnerable Populations

Espace Confiance, in collaboration with Sidaction,  
Paris, France  
Abidjan, Côte-d'Ivoire  
\$9,000

##### Improving Access to HIV/AIDS Treatment for Mombasa's MSM Community

PEMA Kenya  
Mombasa, Kenya  
\$10,077

#### Asia-Pacific

##### Promoting Risk Reduction Behaviours Among MSM

Bandhu Social Welfare Society  
Dhaka, Bangladesh  
\$29,998

##### Legal Support to Chinese Grassroots MSM NGOs in Their HIV-Related Activities

Chengdu Tongle Counseling & Service Center  
Chengdu, China  
\$15,000

##### Field-Based Oral HIV Testing and Linkage to Government Care in a High HIV Prevalence Region of India

Name withheld by request  
Secunderabad, India  
\$29,728

#### Caribbean

##### Health Empowerment Through Leadership Development and Information

United Belize Advocacy Movement  
Belize City, Belize  
\$15,000

##### Project "As I Am"

Centro de Orientación e Investigación Integral  
Santo Domingo, Dominican Republic  
\$30,000

##### Strengthening Community Cohesion and Building Resilience to HIV in Guyana

Society Against Sexual Orientation Discrimination  
Georgetown, Guyana  
\$15,000

##### Access Project

Gay and Lesbian Coalition of Kenya, in partnership with Ishtar MSM  
Nairobi, Kenya  
\$13,800

##### HIV/AIDS Awareness, Advocacy, and Prevention Campaign Targeting MSM: Access to Health and Sexual Rights in Liberia

Stop AIDS in Liberia  
Monrovia, Liberia  
\$15,000

##### Establishment of a Drop-in Centre for MSM in Marrakesh City

Association de Lutte Contre le Sida  
Marrakesh, Morocco  
\$15,000

##### HIV/AIDS Prevention and Support Among Sexually Active MSM in Makassar, South Sulawesi Province, Indonesia

Yayasan Gaya Celebes  
Makassar, South Sulawesi, Indonesia  
\$15,000

##### HIV Intervention for Hidden MSM Community of Pakistan

Red Ribbon Initiative  
Islamabad, Pakistan  
\$14,975

##### Transgender Outreach Program

Action for AIDS Singapore  
Singapore  
\$15,980

##### Evidence-Based, MSM-Led HIV Prevention and Anti-Stigma Program

Fondation Esther Boucicault Stanislas  
Saint-Marc, Haiti  
\$15,000

##### Increasing Equitable Access to Prevention for MSM in Haiti

SEROvie  
Port-au-Prince, Haiti  
\$15,000

##### To Support Religious Leaders in Carrying Out Effective HIV and AIDS Responses Targeting MSM and Gay, Bisexual and Transgenders Through Their Faith Communities

South African Network of Religious Leaders Living with or Personally Affected by HIV & AIDS  
Johannesburg, South Africa  
\$15,000

##### HIV/AIDS Prevention and Treatment Information

Name withheld by request  
Kampala, Uganda  
\$15,000

##### Sero-prevalence Study for Zambian MSM

Friends of RAINKA  
Lusaka, Zambia  
\$15,750

##### Expanding HIV Prevention and Outreach Coverage @ Mplus+

Mplus+  
Chiang Mai, Thailand  
\$15,000

##### MSM Sex Workers in Hanoi: High Risks and

Barriers to HIV Prevention  
STD/HIV/AIDS Prevention Center  
Hanoi, Vietnam  
\$15,000

##### Bringing Hope, Building Community

Jamaica Forum for Lesbians, All-Sexuals and Gays  
Kingston, Jamaica  
\$15,000

##### Regional Prevention Response to HIV/AIDS Vulnerability Among MSM Populations in the Caribbean

MSM: No Political Agenda  
Santa Cruz, Trinidad and Tobago  
\$15,000

## Eastern Europe and Central Asia

### Human Rights Advocacy and HIV/AIDS Prevention, Care, and Support for MSM Communities in Armenia

We For Civil Equality  
Yerevan, Armenia  
\$14,560

### HIV Prevention Intervention Among MSM in Chui and Osh Regions of Kyrgyzstan

Public Fund Gender-Vector  
Karabalta, Kyrgyzstan  
\$10,000

### Prevention of HIV for MSM Through Information, Peer Counseling, and Community Mobilization and Advocacy

New Life Organization  
Orenburg, Russia  
\$15,000

## Latin America

### Adesproc Libertad GLBT

Asociacion Civil de Desarrollo Social y Promocion Cultural Adesproc Libertad GLBT  
La Paz, Bolivia  
\$7,300

### Taking Care of My Life

Asociación Un Nuevo Camino  
La Paz, Bolivia  
\$15,000

### Adherence to Treatment, Citizenship and Increasing Incomes of HIV-Positive Transvestites

Articulação e Movimento para Travestis e Transexuais de Pernambuco  
Recife, Brazil  
\$9,500

### Merchants of Illusions Project

Name withheld by request  
Recife, Brazil  
\$10,000

## MSM INITIATIVE AWARDS TO COLLABORATING ORGANIZATIONS

### Be Heard: Global Forum on MSM and HIV Pre-conference Event—IAC 2010

AIDS Project Los Angeles as secretariat for the Global Forum on MSM and HIV  
Los Angeles, CA  
\$10,000

## Public Policy Awards

All projects listed below were supported by amfAR during the period from October 1, 2009, to September 30, 2010.

### Federal Funding for Syringe Exchange

Don Des Jarlais, Ph.D.  
Beth Israel Medical Center/Chemical Dependency Institute  
New York, NY  
\$40,000

### Syringe Exchange in the U.S., 2009-2010: Assessing a Changing Landscape

Don Des Jarlais, Ph.D.  
Beth Israel Medical Center/ Chemical Dependency Institute  
New York, NY  
\$75,000

### HIV Prevention and Psychosocial Support for MSM in Prisons: Scaling Up

Nikolaev Regional Public Youth Movement—Penitentiary Initiative  
Nikolaev, Ukraine  
\$30,000

### Participatory Approach to Evidence-based Planning, Establishing, and Conducting Counseling Centers for MSM

Safe Pulse of Youth  
Belgrade, Serbia  
\$14,980

### HIV and Other Socially Significant Diseases Among MSM

CSO Equal Opportunities  
Dushanbe, Tajikistan  
\$15,000

### Comprehensive Care for Indigenous MSM Communities affected by HIV/AIDS in the Northern Guajira Peninsula Region of Colombia

Akuaipa Waimakat—Asociación para la Divulgación, Promoción y Defensa de los Derechos Humanos e Indígenas  
Manaure, Colombia  
\$13,900

### Transgender Incidence

Asociación ALFIL  
Quito, Ecuador  
\$15,000

### We Are Healthy

Asociación Solidaria Para Impulsar el Desarrollo Humano (“ASPIDH—ACRO IRIS”)  
San Salvador, El Salvador  
\$14,993

### MSM Against HIV

Colectivo SerGay de Aguascalientes, A.C.  
Aguascalientes, Mexico  
\$15,000

### Intervention, Prevention and Testing for MSM in Puerto Vallarta

Vallarta Enfrenta el SIDA, A.C.  
Puerto Vallarta, Mexico  
\$15,000

### Case Management: Surveying Adherence to Antiretroviral Treatment for HIV+ MSM in Panamá

Grupo Génesis Panamá Positivo  
Panamá City, Panamá  
\$12,716

# Message from the Treasurer and the Chair of the Finance and Budget Committee

We are pleased to present the audited financial statements of amfAR, The Foundation for AIDS Research, for the fiscal year ending September 30, 2010.

Although the effects of the global economic downturn persisted throughout 2010, amfAR's prudent financial management and the growing success of its fundraising efforts meant that the organization was able to better its budget projections and end the year with an operating surplus of \$2.3 million, more than making up for last year's \$2 million deficit. With public support and revenue rising to \$26.4 million, 14 percent above FY09, the Foundation has been able to move forward with long-range plans to expand its research commitments.

amfAR's operational efficiency and its effective use of donor contributions during 2010 are illustrated by two key figures. The supporting services ratio—the ratio of fundraising and management expenses to total support and revenue—was a low 23.6 percent, while the program spending ratio was a healthy 74.1 percent—meaning that 74 cents out of every dollar spent was invested directly in critical program activities. Program spending was lower in 2010 than in the previous year as a result of careful retrenchment decisions made during the height of the financial crisis in 2009. But this caution, combined with a \$2.8 million increase in special events revenues, allowed amfAR to move forward with plans for programmatic expansion in FY2011.

The Foundation's steady growth in 2010 was accompanied by important programmatic advances. In May 2010, amfAR launched one of the most ambitious and far-reaching research initiatives in its 25-year history. The amfAR Research Consortium on HIV Eradication (ARCHE) announced \$1.2 million in grants to four collaborative teams of senior scientists who are actively pursuing a cure for AIDS. amfAR's commitment to a cure has helped catalyze a surge of interest in cure research, and ARCHE is the centerpiece of its efforts to move this goal forward. TREAT Asia and the MSM Initiative continued to expand their international activities, and amfAR's public policy office worked tirelessly to promote the needs and protect the rights of people living with HIV and vulnerable to infection.

In 2010, amfAR again met the stringent requirements of governance and financial accountability demanded by the Better Business Bureau's Wise Giving Alliance and the federal government's workplace fundraising program, the Combined Federal Campaign, as well as many state employee workplace giving campaigns.

A copy of the complete audited financial statements, prepared in accordance with generally accepted accounting principles for not-for-profit organizations as established by the American Institute of Certified Public Accountants, is available upon request from amfAR at 120 Wall Street, 13th Floor, New York, NY 10005, and can be accessed by visiting [www.amfar.org](http://www.amfar.org).



**Wallace Sheft, C.P.A.**  
Treasurer



**Michael J. Klingensmith**  
Chair, Finance and Budget Committee



## Financial Highlights




For the year ended September 30, 2010


<b>Public Support and Revenue</b>		
Public support	\$	6,531,572
Special events		9,951,810
Planned giving		2,541,156
Government funding		5,959,900
Investment income and other revenue		1,259,618
<b>Total public support and revenue</b>	<b>\$</b>	<b>26,244,056</b>
<hr/>		
<b>Expenses</b>		
Research	\$	6,365,071
TREAT Asia		5,480,584
MSM Initiative		1,863,143
Public Policy		1,569,505
Public Information		2,445,829
<b>Total program services</b>	<b>\$</b>	<b>17,724,132</b>
<hr/>		
Fundraising		4,232,300
Management and general		1,955,217
<b>Total supporting services</b>	<b>\$</b>	<b>6,187,517</b>
<hr/>		
<b>Total expenses</b>	<b>\$</b>	<b>23,911,649</b>
<hr/>		
Change in net assets		2,332,407
Net assets, beginning of year		28,233,359
<b>Net assets, end of year</b>	<b>\$</b>	<b>30,565,766</b>

## Statement of Financial Position






<b>Assets</b>		
Cash and investments	\$	25,033,610
Pledges and receivables		9,331,991
Prepaid expenses and other assets		967,271
Furniture, equipment, and leasehold improvements		471,557
<b>Total Assets</b>	<b>\$</b>	<b>35,804,429</b>
<hr/>		
<b>Liabilities</b>		
Accounts payable and accrued expenses	\$	1,644,227
Grants and fellowships payable, net		573,764
Deferred support and refundable advances		2,679,898
Other long-term liabilities		340,744
<b>Total liabilities</b>	<b>\$</b>	<b>5,238,663</b>
<hr/>		
<b>Total net assets</b>		<b>30,565,766</b>
<hr/>		
<b>Total liabilities and net assets</b>	<b>\$</b>	<b>35,804,429</b>


## Expenses




	Fundraising	\$	4,232,300
	Management and general		1,955,217
	Program		17,724,132
<b>Total</b>		<b>\$</b>	<b>23,911,649</b>



## Program Expenses

	Research	\$	6,365,071
	TREAT Asia		5,480,584
	MSM Initiative		1,863,143
	Public Policy		1,569,505
	Public Information		2,445,829
<b>Total</b>		<b>\$</b>	<b>17,724,132</b>





# Board of Trustees

Fiscal Year 2010

## Chairman of the Board

**Kenneth Cole**  
Chairman  
Kenneth Cole Productions  
New York, NY

## Vice Chairman

**Patricia J. Matson**  
Senior Vice President, Communications (ret.)  
ABC, Inc.  
New York, NY

## Vice Chairman

**John C. Simons**  
Managing Partner  
Corporate Fuel Partners LLC  
New York, NY

## Treasurer

**Wallace Sheft, C.P.A.**  
Partner  
Sheft & Co  
Westbury, NY

## Secretary

**Diana L. Taylor**  
Managing Director  
Wolfensohn & Co. LLC  
New York, NY

## Founding International Chairman

**\*Dame Elizabeth Taylor**  
Actress  
Bel Air, CA

## Founding Chairman

**Mathilde Krim, Ph.D.**  
Adjunct Professor  
Mailman School of Public Health  
Columbia University  
New York, NY

\*Deceased March 23, 2011

## TRUSTEES

**Arlen H. Andelson**  
Andelson Properties  
Los Angeles, CA

**Harry Belafonte**  
President  
Belafonte Enterprises, Inc.  
New York, NY

**David Bohnett**  
Chairman  
David Bohnett Foundation  
Beverly Hills, CA

**Zev Braun**  
President and CEO  
Braun Entertainment Group, Inc.  
Beverly Hills, CA

**Jonathan S. Canno**  
New York, NY

**Donald Capoccia**  
Managing Principal  
BFC Partners  
Brooklyn, NY

**R. Martin Chavez, Ph.D.**  
Managing Director  
Goldman, Sachs & Co.  
New York, NY

**Jane B. Eisner**  
President  
The Eisner Foundation  
Bel Air, CA

**Regan Hofmann**  
Editor-in Chief  
POZ Magazine  
New York, NY

**Michael J. Klingensmith**  
CEO and Publisher  
Minneapolis Star Tribune  
Minneapolis, MN

**Michele V. McNeill, Pharm.D.**  
Chairman  
McNeill Family Foundation  
Long Boat Key, FL

**Richard H. Metzner**  
Principal  
Metzner-Schneider Associates  
Dallas, TX

**Edward L. Milstein**  
Co-Chairman  
Milstein Brothers Capital Partners  
New York, NY

**Cindy D. Rachofsky**  
Philanthropist  
Dallas, TX

**Vincent A. Roberti**  
Chairman and CEO  
Palisades Media Corp.  
New York, NY

**Alan D. Schwartz**  
Executive Chairman  
Guggenheim Partners LLC  
New York, NY

**Mervyn F. Silverman, M.D., M.P.H.**  
President  
Mervyn F. Silverman Associates, Inc.  
Crockett, CA

**Kevin Wendle**  
Entrepreneur  
New York, NY

## ADJUNCT TRUSTEES

**David E. Bloom, Ph.D.**  
Chair, Dept. of Population and International Health  
Harvard School of Public Health  
Boston, MA

**Mario Stevenson, Ph.D.**  
Director, Center for AIDS Research  
University of Massachusetts Medical School  
Worcester, MA

## TRUSTEES EMERITI

**Arthur J. Ammann, M.D.**  
President, Global Strategies for HIV Prevention  
Clinical Professor of Pediatrics  
University of California, San Francisco  
Medical Center  
San Rafael, CA

**Arnold W. Klein, M.D.**  
Professor of Medicine/Dermatology  
University of California, Los Angeles  
Beverly Hills, C



## HONORARY TRUSTEES

**Mouna E. Ayoub**  
Paris, France

**John F. Breglio, Esq.**  
Paul, Weiss, Rifkind, Wharton & Garrison  
New York, NY

**Robert L. Burkett**  
The Carmen Group  
Washington, D.C.

**Michael Fuchs**  
New York, NY

**Sandra Hernández, M.D.**  
Chief Executive Officer  
The San Francisco Foundation  
San Francisco, CA

**Sherry Lansing**  
Chief Executive Officer/Founder  
The Sherry Lansing Foundation  
Los Angeles, CA

**Jane F. Nathanson**  
Psychologist  
Chair, Jane & Marc Nathanson Community  
Foundation  
Los Angeles, CA

**The Rev. Dr. Randolph Nugent**  
General Secretary (ret.)  
General Board of Global Ministries  
United Methodist Church  
New York, NY

**Pauline Phillips**  
Nationally Syndicated Columnist (ret.)  
Los Angeles, CA

**Leonard Rabinowitz**  
President  
Studio CL  
Los Angeles, CA

**Michael D. Shriver**  
Co-Director, AIDS Policy Research Center  
AIDS Research Institute  
University of California, San Francisco  
San Francisco, CA

## IN MEMORIAM

Sheldon W. Andelson, Esq.  
Mrs. Albert D. Lasker  
Jonathan M. Mann, M.D., M.P.H.

Maxine Mesinger  
Natasha Richardson  
Allan Rosenfield, M.D.

Peter Scott, Esq.  
Tom Stoddard  
Joel D. Weisman, D.O.

## BOARD COMMITTEES

### Executive Committee

Kenneth Cole, Chair  
Michael J. Klingensmith  
Mathilde Krim, Ph.D.  
Patricia J. Matson  
Wallace Sheft, C.P.A.  
Mervyn Silverman, M.D., M.P.H.  
John Simons  
Diana L. Taylor

### Audit Committee

Wallace Sheft, C.P.A., Chair  
R. Martin Chavez, Ph.D.  
John C. Simons

### Board Development Committee

**Chair (vacant)**  
Zev Braun  
Jane B. Eisner  
Mathilde Krim, Ph.D.  
Patricia J. Matson  
Alan D. Schwartz

### Compensation and Organizational Development Committee

John C. Simons, Chair  
Michael J. Klingensmith  
Richard H. Metzner

### Finance & Budget Committee

Michael J. Klingensmith, Chair  
Vincent A. Roberti  
John C. Simons

### Fund Development Committee

Vincent A. Roberti, Chair  
Jonathan S. Canno  
Edward L. Milstein

## Scientific Advisory Committee

### **Mario Stevenson, Ph.D. (Chair)**

Director, Center for AIDS Research  
University of Massachusetts Medical School  
Worcester, MA

### **Sherry Deren, Ph.D. (Co-Chair)**

Director, Center for Drug Use and HIV Research  
Senior Research Scientist  
New York University College of Nursing

### **Deborah Anderson, Ph.D.**

Professor and Director  
Division of Reproductive Biology  
Boston University School of Medicine

### **Warren A. Andiman, M.D.**

Professor of Pediatrics, Epidemiology and Public Health  
Department of Pediatrics  
Yale University School of Medicine

### **Jose Arturo Bauermeister, M.P.H., Ph.D.**

Research Assistant Professor  
Department of Health Behavior and Health Education  
University of Michigan

### **Michael Belshan, Ph.D.**

Assistant Professor  
Department of Medical Microbiology and Immunology  
Creighton University

### **Jason Brenchley, Ph.D.**

Tenure-Track Investigator  
Laboratory of Molecular Microbiology  
National Institute of Allergy and Infectious Diseases, National Institutes of Health

### **Dennis R. Burton, Ph.D.**

Professor  
Department of Immunology  
The Scripps Research Institute

### **Salvatore T. Butera, D.V.M., Ph.D.**

Chief  
Virology Section  
Centers for Disease Control and Prevention

### **Edward Campbell, Ph.D.**

Assistant Professor  
School of Medicine  
Loyola University Chicago

### **Alex Carballo-Dieiguez, Ph.D.**

Research Scientist and Professor of Clinical Psychology  
Department of Psychology  
Columbia University

### **Larry Williams Chang, M.D., Ph.D.**

Department of Medicine  
Johns Hopkins University

### **David B. Clifford, M.D.**

Professor  
Department of Neurology  
Washington University School of Medicine

### **Eric Cohen, Ph.D.**

Research Unit Director  
Department of Human Retrovirology  
Institut de recherches cliniques de Montréal

### **C. Budd Colby, Ph.D.**

Colby Biomedical Consultants

### **Grant Colfax, M.D.**

Director of HIV Prevention and Research  
San Francisco Department of Public Health

### **Deborah Jean Cotton, M.D., M.P.H.**

Professor of Medicine  
Department of Medicine  
Boston University School of Medicine

### **Bryan Richard Cullen, Ph.D.**

Professor  
Department of Genetics  
Duke University Medical Center

### **Susanna Cunningham-Rundles, Ph.D.**

Professor of Immunology  
Department of Pediatrics  
Cornell University Medical College

### **Richard Thomas D'Aquila, M.D.**

Addison B. Scoville Professor of Medicine  
Department of Medicine  
Vanderbilt University School of Medicine

### **Ronald C. Desrosiers, Ph.D.**

Professor of Microbiology and Molecular Genetics  
Harvard Medical School

### **Roger Detels, M.D., M.S.**

Professor of Epidemiology  
School of Public Health  
University of California, Los Angeles

### **Carl W. Dieffenbach, Ph.D.**

Director, Basic Sciences Program  
Division of AIDS  
National Institute of Allergy and Infectious Diseases, National Institutes of Health

### **Daniel C. Douek, M.D., Ph.D.**

Chief, Human Immunology Section  
Vaccine Research Center  
National Institute of Allergy and Infectious Diseases, National Institutes of Health

### **D. Peter Drotman, M.D., M.P.H.**

Editor-in-Chief  
Emerging Infectious Diseases  
Centers for Disease Control and Prevention

### **Anke A. Ehrhardt, Ph.D.**

Director and Professor  
Department of Psychiatry  
Columbia University

### **Homayoon Farzadegan, Ph.D.**

Professor  
Department of Epidemiology  
Johns Hopkins University

### **Dianne M. Finkelstein, Ph.D.**

Director of Biostatistics  
Cancer Center Biostatistics  
Massachusetts General Hospital and Harvard Medical School

### **Alan Frankel, Ph.D.**

Professor  
Department of Biochemistry and Biophysics  
University of California, San Francisco

### **Gerald Herbert Friedland, M.D.**

Professor and Director, AIDS Program  
Department of Internal Medicine  
Yale School of Medicine

### **Victor Garcia-Martinez, Ph.D.**

Professor of Medicine, School of Medicine  
Center for Infectious Diseases  
University of North Carolina, Chapel Hill

### **Howard E. Gendelman, M.D.**

David T. Purtilo Professor of Pathology and Microbiology  
Department of Pathology and Microbiology  
University of Nebraska Medical Center

### **Stephen P. Goff, Ph.D.**

Higgins Professor of Microbiology & Immunology and Biochemistry & Molecular Biophysics  
Howard Hughes Medical Institute  
Columbia University

### **Nancy L. Haigwood, Ph.D.**

Director and Senior Scientist  
Division of Pathobiology & Immunology  
Oregon National Primate Research Center

### **Dean Hamer, Ph.D.**

Senior Investigator and Head  
Gene Structure and Regulation Section  
National Cancer Institute, National Institutes of Health

### **Daria Hazuda, Ph.D.**

Vice President of Virus and Cell Biology  
Department of Antiretroviral Research, Molecular Endocrinology, Virus and Cell Support, and Medicinal Chemistry  
Merck Research Laboratories

### **Charles H. Hinkin, Ph.D.**

Associate Professor  
Department of Psychiatry and Biobehavioral Science  
University of California School of Medicine

### **David Ho, M.D.**

Scientific Director, Chief Executive Officer  
Irene Diamond Professor  
Aaron Diamond AIDS Research Center

### **Thomas J. Hope, Ph.D.**

Professor  
Department of Cell and Molecular Biology  
Northwestern University Feinberg School of Medicine

### **Keith J. Horvath, Ph.D.**

Assistant Professor  
School of Public Health  
University of Minnesota

### **Shiu-Lok Hu, Ph.D.**

Professor  
School of Pharmacy  
University of Washington

### **Kuan Teh Jeang, Ph.D.**

Chief  
Medical Virology Section  
National Institute for Allergy and Infectious Diseases, National Institutes of Health



**Fatah Kashanchi, Ph.D.**  
Professor  
Department of Biochemistry and Molecular  
Biology  
George Washington University Medical Center

**Ronald C. Kennedy, Ph.D.**  
Chairman and Professor  
Department of Microbiology and Immunology  
Texas Tech University Health Sciences Center

**Vineet KewalRamani, Ph.D.**  
Chief, Model Development Section  
HIV Drug Resistance Program  
National Cancer Institute, National Institutes of  
Health

**Richard Kornbluth, M.D., Ph.D.**  
Associate Professor of Medicine  
Department of Medicine  
University of California, San Diego

**Richard A. Koup, M.D.**  
Chief, Immunology Laboratory  
Vaccine Research Center  
National Institute of Allergy and Infectious  
Diseases, National Institutes of Health

**Priti Kumar, Ph.D.**  
Assistant Professor  
Yale School of Medicine

**Nathaniel R. Landau, Ph.D.**  
Professor  
Department of Microbiology  
New York University School of Medicine

**Alan L. Landay, Ph.D.**  
Professor and Associate Chairman  
Department of Immunology and Microbiology  
Rush-Presbyterian-St.Luke's Medical Center

**Jeffrey Laurence, M.D.**  
Professor of Medicine  
Director, Laboratory for AIDS Virus Research  
Weill Medical College of Cornell University

**Michael Lederman, M.D.**  
Professor of Medicine, Director  
Center for AIDS Research  
Case Western Reserve University

**Tun-Hou Lee, D.Sc.**  
Professor of Virology  
Department of Immunology and Infectious  
Diseases  
Harvard School of Public Health

**Michael J. Leibowitz, M.D., Ph.D.**  
Professor  
Department of Molecular Genetics and  
Microbiology  
University of Medicine and Dentistry of New  
Jersey-Robert Wood Johnson Medical School

**Robert J. Levine, M.D.**  
Professor of Medicine  
Center for Interdisciplinary Research on AIDS  
Yale University

**Judy Lieberman, M.D., Ph.D.**  
Senior Investigator  
Immune Disease Institute  
Professor of Pediatrics  
Harvard Medical School

**Manuel Llano, M.D., Ph.D.**  
Assistant Professor  
Department of Biological Sciences  
University of Texas, El Paso

**Shan Lu, Ph.D., M.D.**  
Professor  
Department of Immunology and Virology  
University of Massachusetts Medical School

**Hinh Ly, Ph.D.**  
Assistant Professor  
Pathology & Laboratory Medicine Department  
Emory University School of Medicine

**H. Kim Lyerly, M.D.**  
Professor in Surgery, Immunology, Pathology  
Duke Comprehensive Cancer Institute  
Duke University Medical Center

**Harmit Malik, Ph.D.**  
Principal Investigator  
Division of Basic Sciences  
Fred Hutchinson Cancer Research Center

**David M. Margolis, M.D.**  
Professor of Microbiology, Medicine and Public  
Health  
School of Medicine  
University of North Carolina, Chapel Hill

**Martin H. Markowitz, M.D.**  
Staff Investigator  
Aaron Diamond AIDS Research Center

**Kenneth Hugh Mayer, M.D.**  
Chief, Division of Infectious Diseases  
Immunology Center  
Miriam Hospital  
Professor of Medicine and Community Health  
Brown University

**Joseph M. McCune, M.D., Ph.D.**  
Professor of Medicine  
Division of Experimental Medicine  
University of California, San Francisco

**Donna Mildvan, M.D.**  
Chief  
Department of Medicine  
Beth Israel Medical Center

**Jay A. Nelson, Ph.D.**  
Professor and Director  
Division of Pathobiology and Immunology  
Oregon Health Sciences University

**Nancy Padian, M.P.H., Ph.D.**  
Distinguished Fellow  
Women's Global Health Imperative  
RTI International

**Savita Pahwa, M.D.**  
Director  
Microbiology and Immunology  
Leonard M. Miller School of Medicine  
University of Miami

**Deborah Palliser, Ph.D.**  
Assistant Professor  
Department of Microbiology & Immunology  
Albert Einstein College of Medicine

**Tristram G. Parslow, M.D., Ph.D.**  
William Patterson Timmie Professor and Chair  
Department of Pathology and Laboratory Medicine  
Emory University School of Medicine

**Matija Peterlin, M.D.**  
Professor  
Department of Medicine  
University of California, San Francisco

**Lynn Pulliam, Ph.D.**  
Professor in Residence  
Chief of Microbiology  
Department of Laboratory Medicine and Medicine  
University of California, San Francisco/Veterans  
Affairs Medical Center

**Han-Zhu Qian, M.D., Ph.D.**  
Assistant Professor of Medicine  
Vanderbilt Institute for Global Health  
Vanderbilt University

**Lee Ratner, M.D., Ph.D.**  
Professor  
Department of Medicine  
Washington University School of Medicine

**Scott Rhodes, Ph.D., M.P.H, C.H.E.S.**  
Associate Professor  
Department of Social Sciences and Health Policy  
Wake Forest University School of Medicine

**Andrew Rice, Ph.D.**  
Professor  
Department of Molecular Virology and  
Microbiology  
Baylor College of Medicine

**Cornelis A. Rietmeijer, M.D., Ph.D.**  
Director, STD Control Program  
Denver Public Health Department

**Melissa Robbiani, Ph.D.**  
Sr. Scientist and Director of Biomedical HIV  
Research  
Center for Biomedical Research  
Population Council

**Ruth M. Ruprecht, M.D., Ph.D.**  
Professor of Medicine  
Department of Cancer Immunology and AIDS  
Dana-Farber Cancer Institute and Harvard Medical  
School

**Frederick A. Schmitt, Ph.D.**  
Associate Professor  
Departments of Neurology, Psychiatry &  
Psychology  
University of Kentucky Medical Center

**Gerald Schochetman, Ph.D.**  
Director, AIDS Research and Retrovirus Discovery  
Abbott Laboratories

**Robert Turner Schooley, M.D.**  
Academic Vice Chair  
Professor and Head  
Department of Medicine/Division of Infectious  
Diseases  
University of California, San Diego

**Ann M. Sheehy, Ph.D.**  
Assistant Professor  
Biology Department  
College of the Holy Cross

**Frederick P. Siegal, M.D.**  
Chief, Section of HIV Medicine and Medical Director  
Department of Medicine  
Saint Vincent's Hospital and Medical Center

**Gail Skowron, M.D.**  
Associate Professor of Medicine  
Department of Medicine, Division of Infectious Diseases  
Roger Williams Medical Center

**Leonidas Stamatatos, Ph.D.**  
Full Member and Director of Viral Vaccines Program  
Seattle Biomedical Research Institute

**Klaus Strelbel, Ph.D.**  
Chief, Viral Biochemistry Section  
Laboratory of Molecular Microbiology  
National Institute of Allergy and Infectious Diseases, National Institutes of Health

**Lishan Su, Ph.D.**  
Associate Professor  
Department of Microbiology and Immunology  
University of North Carolina-Chapel Hill

**Ernest F. Terwilliger, Ph.D.**  
Assistant Professor  
Beth Israel Deaconess Medical Center

**Barbara Visscher, M.D., Dr.P.H.**  
Professor of Epidemiology  
Department of Epidemiology  
University of California, Los Angeles

**David Vlahov, Ph.D.**  
Director  
Center for Urban Epidemiologic Studies  
New York Academy of Medicine

**David J. Volsky, Ph.D.**  
Professor and Director  
Department of Pathology and Medicine  
St. Luke's-Roosevelt Hospital Center and Columbia University

**Mark A. Wainberg, Ph.D.**  
Professor and Director  
McGill AIDS Centre  
McGill University

**Steven S. Witkin, Ph.D.**  
Professor and Director  
Department of Obstetrics and Gynecology  
Weill Medical College of Cornell University

**Peter R. Wolfe, M.D.**  
Los Angeles, California

**Richard T. Wyatt, Ph.D.**  
Professor of Immunology  
International AIDS Vaccine Initiative Center for Neutralizing Antibodies  
Scripps Research Institute

**Xiao-Fang Yu, M.D., D.Sc.**  
Professor  
Department of Molecular Microbiology and Immunology  
Bloomberg School of Public Health  
Johns Hopkins University

## Program Advisory Council

**Mervyn Silverman, M.D., M.P.H. (Chairman)**  
President  
Mervyn F. Silverman Associates, Inc.

**David Bloom, Ph.D. (Co-chairman)**  
Chair, Department of Global Health and Population  
Harvard School of Public Health

**Mario Stevenson, Ph.D. (Co-chairman)**  
Professor of Medicine, Chief, Division of Infectious Diseases  
University of Miami  
Leonard M. Miller School of Medicine

**Tim Brown, Ph.D.**  
Senior Fellow  
The East-West Center

**Daria J. Hazuda, Ph.D.**  
Vice President  
Worldwide Franchise Discovery Head for Antivirals  
Merck & Company, Inc.

**Kenneth H. Mayer, M.D.**  
Professor of Medicine and Community Health  
Brown University, Alpert Medical School  
Infectious Diseases Division  
The Miriam Hospital  
Medical Research Director  
Fenway Health

**Jeffrey L. Sturchio, Ph.D.**  
President and Chief Executive Officer  
The Global Health Council

## Management Group

**Kevin Robert Frost**  
Chief Executive Officer

**Anthony Ancona**  
Vice President and Director, Human Resources

**Susan J. Blumenthal, M.D., M.P.A.**  
Senior Policy and Medical Advisor

**Gregory Boroff, C.A.E., C.F.R.E.**  
Vice President and Director, Development

**Chris Collins, M.P.P.**  
Vice President and Director, Public Policy

**Bradley Jensen**  
Chief Financial Officer

**Rowena Johnston, Ph.D.**  
Vice President and Director, Research


**Jeffrey Laurence, M.D.**  
Senior Scientific Consultant for Programs

**John F. Logan, Ph.D., J.D.**  
Vice President and General Counsel

**AnnMari Shannahan**  
Vice President, Public Information

**Annette Sohn, M.D.**  
Vice President and Director, TREAT Asia





amfAR, The Foundation for AIDS Research

NEW YORK

120 Wall Street, 13th Floor  
New York, NY 10005-3908  
(212) 806-1600 (tel)  
(212) 806-1601 (fax)

WASHINGTON, D.C.

1150 17th Street, NW  
Suite 406  
Washington, DC 20036-4622  
(202) 331-8600 (tel)  
(202) 331-8606 (fax)

BANGKOK, THAILAND

TREAT Asia  
Exchange Tower  
388 Sukhumvit Road, Suite 2104  
Klongtoey, Bangkok 10110  
Thailand  
+66 (0)2 663 7561 (phone)  
+66 (0)2 663 7562 (fax)

[www.amfar.org](http://www.amfar.org)